Cabolin 0.5mg (4pcs box)

Indications of Cabolin 0.5 Tablet

It is demonstrated for the treatment of hyperprolactinemic clutters, either idiopathic or due to pituitary adenomas. It is utilized to halt breast drain generation (lactation) before long after childbirth, stillbirth, fetus removal or premature delivery. It can moreover be utilized to treat other conditions caused by hormonal unsettling influence which can result in tall levels of prolactin being delivered. This incorporates tall levels of prolactin caused by tumors of the pituitary organ in both men and ladies.

Pharmacology of Cabolin 0.5 Tablet

Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. It works by reducing the amount of prolactin that is released from pituitary gland. Results of in vitro studies demonstrate that Cabergoline exerts a direct inhibitory effect on the secretion of prolactin.

Administration & Dosage of Cabolin 0.5 Tablet

The recommended dosage of Cabergoline Tablet for initiation of therapy is 0.25 mg twice a week. Dosage may be increased by 0.25 mg twice weekly up to a dosage of 1 mg twice a week according to the patient’s serum prolactin level. Before initiating treatment, cardiovascular evaluation should be performed and echocardiography should be considered to assess for valvular disease.

Dosage increases should not occur more rapidly than every 4 weeks. If the patient does not respond adequately, and no additional benefit is observed with higher doses, the lowest dose that achieved maximal response should be used and other therapeutic approaches considered. Patients receiving long term treatment with Cabergoline should undergo periodic assessment of their cardiac status and echocardiography should be considered.After a normal serum prolactin level has been maintained for 6 months, Cabergoline may be discontinued, with periodic monitoring of the serum prolactin level to determine whether or when treatment with Cabergoline should be reinstituted.

To prevent milk production (lactation): 1 mg (two 0.5 mg tablets) on the first day after delivery.

To stop lactation once after start of breastfeeding: 0.25 mg (one half of Cabergoline 0.5 mg table) every 12 hours for two days. To reduce prolactin levels in other conditions: Initially, 0.25 mg twice a week. Dose may be increased up to maximum dose of 4.5 mg or until have responded fully to treatment.

Interaction of Cabolin 0.5 Tablet

Cabergoline ought to not be managed concurrently with D2-antagonists, such as Phenothiazines, Butyrophenones, Thioxanthenes, or Metoclopramide, Chlorpromazine, Domperidone, and medications to lower blood weight.

Contraindications

Cabergoline tablet is contraindicated in patients with: Uncontrolled hypertension or known hypersensitivity History of cardiac valvular clutters exhibit of valve pamphlet thickening High blood weight in pregnancy related with swelling and protein in urine History of pneumonic, pericardial, or retroperitoneal fibrotic clutters & genuine mental malady.

Side Effect of Cabolin 0.5 Tablet

Pathological gambling, increased libido, and hypersexuality have been reported in patients treated with dopamine agonists including cabergoline. This has been generally reversible upon reduction of the dose or treatment discontinuation.

Pregnancy & Lactation

Pregnancy category B. It is not known whether this drug is excreted in human milk.

Precautions & Warnings

Initial doses higher than 1.0 mg may produce orthostatic hypotension. Care should be exercised when administering Cabergoline with other medications known to lower blood pressure, hypersensitivity, severe liver disease & mental illness.

Storage Conditions

Protect from light and moisture by storing below 30°C. Keep the medicine out of children's reach.